Sökning: L773:1471 2598 OR L773:1744 7682 >
Next-generation CD4...
Next-generation CD40 agonists for cancer immunotherapy
-
- Andersson, Hampus (författare)
- Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LTH profilområde: Teknik för hälsa,LTH profilområden,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LTH Profile Area: Engineering Health,LTH Profile areas,Faculty of Engineering, LTH,Alligator Biosciences AB,Alligator Biosci AB, Alligator Biosci, Lund, Sweden; Lund Univ, Dept Immunotechnol, Lund, Sweden
-
- Nyesiga, Barnabas (författare)
- Malmö universitet,Malmö University,Alligator Biosciences AB,Institutionen för biomedicinsk vetenskap (BMV),Alligator Biosci AB, Alligator Biosci, Lund, Sweden
-
- Hermodsson, Tova (författare)
- Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,LTH profilområde: Teknik för hälsa,LTH profilområden,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments,LTH Profile Area: Engineering Health,LTH Profile areas,Faculty of Engineering, LTH,Lund Univ, Dept Immunotechnol, Lund, Sweden
-
visa fler...
-
- Enell Smith, Karin (författare)
- Alligator Biosciences AB,Alligator Biosci AB, Alligator Biosci, Lund, Sweden
-
- Hägerbrand, Karin (författare)
- Alligator Biosciences AB,Alligator Biosci AB, Alligator Biosci, Lund, Sweden
-
- Lindstedt, Malin (författare)
- Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,LTH profilområde: Teknik för hälsa,LTH profilområden,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments,LTH Profile Area: Engineering Health,LTH Profile areas,Faculty of Engineering, LTH,Alligator Biosciences AB,Alligator Biosci AB, Alligator Biosci, Lund, Sweden; Lund Univ, Dept Immunotechnol, Lund, Sweden; Alligator Biosci AB, S-22381 Lund, Sweden
-
- Ellmark, Peter (författare)
- Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Alligator Biosciences AB,Alligator Biosci AB, Alligator Biosci, Lund, Sweden; Lund Univ, Dept Immunotechnol, Lund, Sweden
-
visa färre...
-
(creator_code:org_t)
- TAYLOR & FRANCIS LTD, 2024
- 2024
- Engelska 13 s.
-
Ingår i: Expert Opinion on Biological Therapy. - : TAYLOR & FRANCIS LTD. - 1471-2598 .- 1744-7682. ; 24:5, s. 351-363
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://doi.org/10.1...
-
https://mau.diva-por... (primary) (Raw object)
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an opportunity to meet this need by promoting priming of tumor-specific T cells and reverting the suppressive tumor microenvironment. This is supported by emerging clinical evidence demonstrating the benefits of immunotherapy with CD40 antibodies in combination with standard of care chemotherapy. Areas covered: This review is focused on the coming wave of next-generation CD40 agonists aiming to improve efficacy and safety, using new approaches and formats beyond monospecific antibodies. Further, the current understanding of the role of different CD40 expressing immune cell populations in the tumor microenvironment is reviewed. Expert opinion: There are multiple promising next-generation approaches beyond monospecific antibodies targeting CD40 in immuno-oncology. Enhancing efficacy is the most important driver for this development, and approaches that maximize the ability of CD40 to both remodel the tumor microenvironment and boost the anti-tumor T cell response provide great opportunities to benefit cancer patients. Enhanced understanding of the role of different CD40 expressing immune cells in the tumor microenvironment may facilitate more efficient clinical development of these compounds.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- Antibodies
- antigen-presenting cells
- bispecific antibodies
- CD40
- immuno-oncology
- tumor-associated antigens
- Antibodies
Publikations- och innehållstyp
- for (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas